Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Sclerosing Cholangitis
- Main trialPhase 1
- “The main aim of this study is to see if the drug TAK-781 is safe for healthy volunteers and for participants with PSC. The study will also look at how well participants can tolerate TAK-781. In addition, the study will check how the body absorbs, uses, and gets rid of TAK-781 (Pharmacokinetics \[PK\]), how the drug affects the body (Pharmacodynamics \[PD\]), and how the body's immune system reacts to TAK-781 (Immunogenicity). The study consists of two phases (Phase 1a and 1b). Phase 1a includes two parts: Part 1 (Single Ascending Dose \[SAD\]) and Part 2 (Multiple Ascending Dose \[MAD\]). In…”In the company’s words, NCT07229911 on ClinicalTrials.gov
Other drugs for Primary Sclerosing Cholangitis
- Norucholic acidDr. Falk Pharma GmbH · Phase 3
- ElafibranorIpsen · Phase 3
- MaralixibatMirum Pharmaceuticals, Inc. · Phase 3
- LB-P8LISCure Biosciences · Phase 2
- HK-660SCuromeBiosciences · Phase 2
- VolixibatMirum Pharmaceuticals, Inc. · Phase 2
Coming up1
- 6 Apr 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 6 Apr 2028 | A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026